--- title: "InflaRx Files Q1 2026 Financials with SEC via Form 6-K" type: "News" locale: "en" url: "https://longbridge.com/en/news/285382696.md" description: "InflaRx N.V. has filed a Form 6-K with the SEC for Q1 2026, including unaudited financial statements and management analysis. The filing, signed by CEO Niels Riedemann, updates investors on the company's performance and maintains eligibility for securities issuance. The latest analyst rating for InflaRx (IFRX) is a Buy with a $6.00 price target, though Spark's AI Analyst rates it as Neutral due to weak financial performance. InflaRx is a biotechnology company focused on anti-inflammatory therapies, with operations in Germany and the U.S." datetime: "2026-05-06T12:24:38.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285382696.md) - [en](https://longbridge.com/en/news/285382696.md) - [zh-HK](https://longbridge.com/zh-HK/news/285382696.md) --- # InflaRx Files Q1 2026 Financials with SEC via Form 6-K ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks InflaRx ( (IFRX) ) just unveiled an announcement. InflaRx N.V. has filed a Form 6-K with the U.S. Securities and Exchange Commission for May 2026, incorporating its latest unaudited condensed consolidated financial statements and management’s discussion and analysis for the quarter ended March 31, 2026 into existing shelf and employee share plan registrations. The filing, signed on May 6, 2026 by CEO Niels Riedemann, updates U.S. investors on the company’s operating performance, cash flows and equity movements, underscoring continued transparency and maintaining the company’s eligibility to issue securities under its current SEC-registered programs. The most recent analyst rating on (IFRX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on InflaRx stock, see the IFRX Stock Forecast page. **Spark’s Take on IFRX Stock** According to Spark, TipRanks’ AI Analyst, IFRX is a Neutral. The score is held back primarily by very weak financial performance (minimal/declining revenue, persistent losses, and ongoing cash burn), partially offset by a relatively low-debt balance sheet. Technicals are supportive due to strong upward momentum, but overbought signals add near-term risk, while valuation is difficult to support given negative earnings and no dividend data. To see Spark’s full report on IFRX stock, click here. **More about InflaRx** InflaRx N.V. is a Netherlands-incorporated biotechnology company with principal operations in Jena, Germany, developing anti-inflammatory therapies through its wholly owned subsidiaries in Germany and the United States. The group structures its activities via InflaRx GmbH and InflaRx Pharmaceuticals Inc., and reports its consolidated financial results in euros for global investors. **Average Trading Volume:** 741,262 **Technical Sentiment Signal:** Buy **Current Market Cap:** $154M ### Related Stocks - [IFRX.US](https://longbridge.com/en/quote/IFRX.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) ## Related News & Research - [08:00 ETAvance Clinical Receives Frost & Sullivan's 2026 Global Company of the Year Recognition for Excellence in Biotech CRO Leadership](https://longbridge.com/en/news/286094661.md) - [REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval](https://longbridge.com/en/news/286443456.md) - [](https://longbridge.com/en/news/286807703.md) - [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md) - [Editas Showcases Promising EDIT-401 Hyperlipidemia Preclinical Data](https://longbridge.com/en/news/286407513.md)